WUXI APPTEC shares surged 5.01% during intraday trading, extending a robust rally following the release of its blockbuster interim report.

The company reported first-half revenue of RMB 28.90 billion, a 38.93% year-over-year increase, while adjusted net profit soared 83.2% to RMB 11.57 billion, marking the first time half-year profit surpassed RMB 10 billion. Full-year revenue guidance was significantly raised to RMB 58.5-60.5 billion, well above the prior range of RMB 51.3-53.0 billion. Following the results, major brokers including Citi, Bank of America, and JPMorgan raised their target prices, with JPMorgan noting that second-quarter revenue and adjusted net profit beat estimates by 25% and 47% respectively.

The bullish sentiment was further bolstered by global pharmaceutical giant Eli Lilly's strong first-half revenue growth of 51.22% year-over-year, reinforcing the high prosperity of the global innovative drug supply chain and highlighting the CXO sector's upstream beneficiaries like WUXI APPTEC.